- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Renal Artery Stenosis.
Displaying page 1 of 2.
EudraCT Number: 2010-023002-13 | Sponsor Protocol Number: BAY 86-4875/91759 | Start Date*: 2011-05-11 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of Gadobutrol-enhanced magnetic resonance angiography (MRA) after a single injection of 0.1 mmol/kg of Gadobut... | |||||||||||||
Medical condition: Subjects with known or suspected renal artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016737-95 | Sponsor Protocol Number: ROSPREC | Start Date*: 2011-07-13 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA | |||||||||||||
Full Title: ROSuvastatin Pretreatment to Reduce Embolization during Carotid Artery Stenting | |||||||||||||
Medical condition: Asymptomatic carotid stenosis >80% in patients with baseline LDL cholesterol >120 mg/dL. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000953-46 | Sponsor Protocol Number: SOV301 | Start Date*: 2004-10-13 |
Sponsor Name:Amersham plc | ||
Full Title: A Multicentre, Phase 3, Open-Label, Controlled Study Evaluating the Efficacy and Safety of 0.1 mmol/kg Omniscan (Gadodiamide Injection) in Magnetic Resonance Angiography (MRA) of the Renal Arteries | ||
Medical condition: Renal artery stenosis (RAS) is implicated as the underlying cause in 1% to 5% of patients with hypertension and 5% to 15% of patients with end-stage renal disease entering dialysis programs each ye... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003141-42 | Sponsor Protocol Number: EX9924-4473 | Start Date*: 2019-07-03 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) SK (Ongoing) DE (Ongoing) BE (Ongoing) AT (Ongoing) ES (Ongoing) CZ (Ongoing) HR (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009657-19 | Sponsor Protocol Number: S201 | Start Date*: 2009-11-04 |
Sponsor Name:Ikaria, Inc. | ||
Full Title: A randomized, double-blind, placebo-controlled, multi-center study of IK-1001 to evaluate safety, population pharmacokinetics and proof-of-concept efficacy for reduction of ischemia-reperfusion med... | ||
Medical condition: It will be conducted in subjects undergoing coronary artery bypass graft (CABG) surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004068-21 | Sponsor Protocol Number: PADHIF00805 | Start Date*: 2006-01-11 |
Sponsor Name:Genzyme Europe BV | ||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16 Administered by Intramuscular Injection to Patients with ... | ||
Medical condition: Peripheral Arterial Disease (PAD) with no or poor Chronic Critical Limb Ischemia (CLI) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000061-21 | Sponsor Protocol Number: I1V-MC-EIAN | Start Date*: 2012-10-25 | ||||||||||||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||||||||||||
Full Title: Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study | ||||||||||||||||||||||||||||
Medical condition: High Risk Vascular Disease (HRVD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) SK (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) AT (Completed) ES (Prematurely Ended) LT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013157-15 | Sponsor Protocol Number: 1218.74 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm.V | |||||||||||||
Full Title: A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca... | |||||||||||||
Medical condition: Patients with documented diagnosis of T2DM with insufficient glycaemic control and at high risk of CV events prior to informed consent can be enrolled in the study. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) IE (Completed) FI (Completed) SE (Completed) GB (Completed) SK (Completed) IT (Completed) GR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000860-25 | Sponsor Protocol Number: CSPP100E2337 | Start Date*: 2007-07-27 |
Sponsor Name:Novartis Farmacéutica, SA | ||
Full Title: Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar si la adición de Aliskiren al tratamiento convencional, en pacientes con diabetes tipo 2 y alto riesg... | ||
Medical condition: Diabetes tipo 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended) FR (Completed) FI (Completed) GR (Completed) DE (Completed) DK (Completed) GB (Completed) LT (Completed) BE (Prematurely Ended) HU (Prematurely Ended) NL (Completed) AT (Completed) SE (Prematurely Ended) CZ (Completed) IT (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016178-33 | Sponsor Protocol Number: 1245.25 | Start Date*: 2010-11-12 | |||||||||||
Sponsor Name:Boehringer Ingelheim B.V. | |||||||||||||
Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ... | |||||||||||||
Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006719-20 | Sponsor Protocol Number: 0431-082 | Start Date*: 2009-05-27 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. | |||||||||||||
Full Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control | |||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) LV (Completed) FR (Completed) CZ (Completed) GB (Completed) IE (Prematurely Ended) SK (Completed) BG (Completed) IT (Completed) EE (Completed) FI (Completed) SE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002942-20 | Sponsor Protocol Number: EFC5826 | Start Date*: 2005-12-29 | |||||||||||
Sponsor Name:sanofi-aventis recherche et developpement | |||||||||||||
Full Title: Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obe... | |||||||||||||
Medical condition: Patients with abdominal obesity at increased risk for cardiovascular events (myocardial infarctio, stroke and cardiovascular death) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prohibited by CA) GB (Prematurely Ended) ES (Completed) DE (Completed) AT (Prematurely Ended) FI (Completed) BE (Completed) DK (Suspended by CA) HU (Completed) CZ (Suspended by CA) IE (Prematurely Ended) PT (Completed) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002834-59 | Sponsor Protocol Number: SNFCT2015-05 | Start Date*: 2016-11-28 | |||||||||||||||||||||
Sponsor Name:Sanifit Therapeutics S.A. | |||||||||||||||||||||||
Full Title: A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patie... | |||||||||||||||||||||||
Medical condition: Cardiovascular calcification in blood vessels in end-stage-renal-disease (ESRD) patients on haemodialysis (HD). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004887-24 | Sponsor Protocol Number: NBK182/1/2020 | Start Date*: 2021-04-14 | |||||||||||
Sponsor Name:Marcin Gruchała Medical University of Gdańsk | |||||||||||||
Full Title: Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI) | |||||||||||||
Medical condition: Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002735-28 | Sponsor Protocol Number: I8F-MC-GPGN | Start Date*: 2020-03-30 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT) | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) HU (Ongoing) DE (Ongoing) SK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001824-32 | Sponsor Protocol Number: 116174 | Start Date*: 2015-03-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in pa... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) CZ (Completed) GB (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004505-16 | Sponsor Protocol Number: CONVINCE | Start Date*: 2016-08-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:University College Dublin | ||||||||||||||||||||||||||||||||||||||
Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke | ||||||||||||||||||||||||||||||||||||||
Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: IE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003743-10 | Sponsor Protocol Number: 2016-779 | Start Date*: 2017-02-06 |
Sponsor Name:Herlev og Gentofte Hospital | ||
Full Title: Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at high cardiovascular risk: The SIMPle Randomized Clinical Trial | ||
Medical condition: Type 2 diabetes and cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004144-20 | Sponsor Protocol Number: CHUBX2014/24 | Start Date*: 2015-11-17 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Safety profile evaluation of TICagrelor Alone compared to a combination of lysine acetylsalicylate - Clopidogrel in the context of Transcatheter Aortic Valve Implantation (TAVI) | ||
Medical condition: Aortic valve stenosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001069-28 | Sponsor Protocol Number: D5881C00004 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH) | |||||||||||||
Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.